Domestic biotech company IntoCell is partnering with global contract development and manufacturing organizations (CDMOs) to develop next-generation antibody-drug conjugate (ADC) therapeutics.
On November 3, IntoCell announced that it had signed a memorandum of understanding (MOU) with Xcellon Biologics in the United States and Piramal Pharma Solutions in India for collaboration on next-generation ADC production and technology transfer.
Xcellon Biologics is a US-based CDMO specializing in biopharmaceutical development, offering integrated ADC technology and manufacturing solutions to help clients design and develop ADCs efficiently and quickly while reducing costs. The company also supports the entire process from early-stage research to IND-enabling clinical entry through a flexible and scalable development model.
Piramal Pharma Solutions is the CDMO division of global pharmaceutical company Piramal Pharma, serving as a global partner that provides end-to-end services from drug development to commercial-scale manufacturing.
Both companies are known to possess advanced manufacturing solutions in the fields of biologics and innovative therapeutics.
Through this agreement, IntoCell plans to gradually negotiate terms for technology transfer, the scope of joint research, and commercialization strategies with the two companies, and to pursue joint development projects focusing on the European and US markets.
In particular, IntoCell has secured the right to use a "technology promotion toolbox" that leverages the global pharmaceutical networks of both CDMOs through this agreement. Based on this, the company aims to expand global technology transfer and joint research and development opportunities.
Additionally, IntoCell plans to create synergies for the development and commercialization of next-generation ADC therapeutics by combining its proprietary OHPAS linker, PMT, and Nexatecan payload platform technologies with Xcellon Biologics' development capabilities and Piramal Pharma Solutions' global manufacturing infrastructure.
Previously, in December 2023, IntoCell signed a similar MOU with WuXi XDC, a global CDMO company in China, and is currently continuing its collaboration.
A representative from IntoCell stated, "This agreement is an important first step in expanding IntoCell's proprietary ADC technology to the global market and leading to technology transfer and joint research contracts with various partners. Based on each company's strengths, we will establish a stable and sustainable cooperative structure to accelerate the development of safer and more effective ADC therapeutics for patients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
